Genetic and molecular abnormalities in cholangiocarcinogenesis

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1151-1156

  Hassid, Victor J ^a   Orlando, Frank A ^a   Awad, Ziad T ^a   Dongfeng, T A N ^b   Khoury, Thaer ^c   Ahmed, Bestoun H ^a   Alrawi, Sadir J ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Surgical Oncology Specialties   (United States)

Author keywords

Cholangiocarcinogenesis; Cholangiocarcinoma; Gene; Klatskin tumor; Mechanism; Molecular; Review

Indexed keywords

4 AMINOBUTYRIC ACID; ANGIOPEPTIN; B RAF KINASE; CYCLOOXYGENASE 2; NEUROTRANSMITTER; TAMOXIFEN;

BILE DUCT CARCINOMA; CARCINOGENESIS; DISEASE COURSE; DRUG BINDING; DRUG INHIBITION; HEALTH PROMOTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH; TUMOR PROMOTION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS;

EID: 64949103490     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Shaib YA and El-Serag HB: The epidemiology of cholangio- carcinoma. Semin Liver Dis 24: 115-125, 2004.
2. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357, 2001.
3. Taylor-Robinson SD, Toledano MB, Arora S, Keegan J, Hargreaves S, Beck A, Khan SA, Elliott P and Thomas HC: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48: 816-820, 2001.
4. Lazaridis KN and Gores GJ: Cholangiocarcinoma. Gastroenterology 128: 1655-1667, 2005.
5. Jaiswal M, LaRusso NF, Burgart LJ and Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60: 184-190, 2000.
6. Berthiaume EP and Wands J: The molecular pathogenesis of cholangiocarcinoma, Semin. Liver Dis 24: 127-137, 2004.
7. Marzioni M, Fava G and Benedetti A: Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis, World J Gastroenterology 12: 3471-3480, 2006.
8. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
9. Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15, 2005.
10. Yasoshima M, Kono N, Sugawara H, Katayanagi K, Harada K and Nakanuma Y: Increased expression of interleukin- 6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study. Lab Invest 78: 89-100,1998.
11. Grappone C, Pinzani M, Parola M, Pellegrini G, Caligiuri A, DeFranco R, Marra F, Herbst H, Alpini G and Milani S: Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 31: 100-109, 1999.
12. Tadlock L, Yamagiwa Y, Hawker J, Marienfeld C and Patel T: Transforming growth factor-beta inhibition of proteasomal activity: a potential mechanism of growth arrest. Am J Physiol Cell Physiol 285: C277-C285, 2003.
13. Spirli C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, Larusso NF, Sonzogni A, Okolicsanyi L and Strazzabosco M: Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124: 737-753, 2003.
14. Ishimura N, Bronk SF and Gores GJ: Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 128: 1354- 1368, 2005.
15. Louis AA, Van Eyken P, Haber BA, Hicks C, Weinmaster G, Taub R and Rand EB: Hepatic jagged 1 expression studies. Hepatology 30: 1269-1275, 1999.
16. Milner LA, Bigas A and Kopan R: Inhibition of granulocytic differentiation by mNotchl: Proc Natl Acad Sci USA 93: 13014- 13019,1996.
17. Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA and Kopan R: Embryonic lethality in mice homozygous for a processing-deficient allele of Notchl. Nature 405: 966-970, 2000.
18. Milner LA and Bigas A: Notch as a mediator of cell fate determination in hematopoiesis: evicence and speculation. Blood 93: 243-248, 1999.
19. Miyamoto Y, Maitr A, Ghosh B, Zechner U, Argani P, Iacobuzio- Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM and Leach SD: Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565-576, 2003.
20. Brown JR and DuBois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855, 2005.
21. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, Matsumoto T, Yoshimi N and DiGiovanni J: Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61: 6971-6976,2001.
22. Zhang Z, Lai GH and Sirica AE: Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39: 1028-1037, 2004.
23. Yoon JH, Canbay AE, Werneburg NW, Lee SP and Gores GJ: Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 39: 732- 738, 2004.
24. Haigh WG and Lee SP: Identification of oxysterols in human bile and pigment gallstones. Gastroenterology 121: 118-123, 2001.
25. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K and Tsuneyoshi M: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40: 269-278, 2002.
26. Endo K, Yoon BI, Pairojkul C, Demetris AJ and Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36: 439-450, 2002.
27. Sirica AE, Lai GH, Endo K, Zhang Z and Yoon BI: Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 22: 303-313, 2002.
28. Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC and Sirica AE: ErbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129: 2047- 2057,2005.
29. Lai GH, Radaeva S, Nakamura T and Sirica AE: Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver. Hepatology 31: 1257-1265, 2000.
30. Werneburg NW, Yoon JH, Higuchi H and Gores GJ: Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 285: G31-G36, 2003.
31. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S and Shibata T: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425, 2008.
32. Okada K, Shimizu Y, Nambu S, Higuchi K and Watanabe A: Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9: 462- 467, 1994.
33. Jakowlew SB: Transforming growth factor-beta in cancer and metastasis, Cancer Metastasis Rev 25: 435-457, 2006.
34. Yazumi S, Ko K, Watanabe N, Yoshikawa K, Chiba T and Takahashi R: Disrupted transforming growth factor-beta signaling and deregulated growth in human biliary tract cancer cells. Int J Cancer 86: 782-789, 2000.
35. Zen Y, Harada K, Sasaki M, Chen TC, Chen MF, Yeh TS, Jan YY, Huang SF, Nimura Y and Nakanuma Y: Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta 1 by overexpression of cyclin Dl. Lab Invest 85: 572-581, 2005.
36. Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K and Tanaka M: Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 28: 995-1000,2004.
37. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, Schwarte-Waldhoff I, Maschek H and Schmiegel W: Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 58: 1124-1126, 1998.
38. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, LeRoith D, Torbenson MS, Gores GJ, Wu H, Gao B and Deng CX: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116: 1843- 1852, 2006.
39. Celli A, Que FG, Gores GJ and LaRusso NF: Glutathione depletion is associated with decreased Bel-2 expression and increased apoptosis in cholangiocytes. Am J Physiol Gastrointest Liver Physiol 275: G749-G757, 1998.
40. Okuda K, Nakanuma Y and Miyazaki M: Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 17: 1056-1063, 2002.
41. Torok NJ, Larusso EM and McNiven MA: Alterations in vesicle transport and cell polarity in rat hepatocytes subjected to mechanical or chemical cholestasis. Gastroenterology 121: 1176- 1184,2001.
42. Skopelitou A, Hadjiyannakis M, Alexopoulou V, Krikoni O, Kamina S and Agnantis N: Topographical immunohistochemical expression of bcl-2 protein in human liver lesions. Anticancer Res 16: 975-978, 1996.
43. Harnois DM, Que FG, Celli A, LaRusso NF and Gores GJ: Bcl- 2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 26: 884-890, 1997.
44. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T and Yagura K: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 109: 1612-1617, 1995.
45. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, Muto Y and Furukawa M: Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 49: 604-608, 2002.
46. Torok NJ, Higuchi H, Bronk S and Gores GJ: Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9. Cancer Res 62: 1648-1653, 2002.
47. Ishimura N, Bronk SF and Gores GJ: Inducible nitric oxide synthase up-regulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 287: G88-G95, 2004.
48. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J and Wittekind C: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706-712, 2003.
49. Ura K, Obama K, Satoh S, Sakai Y, Nakamura Y and Furukawa Y: Enhanced RASGEF1A expression is involved in the growth and migration of intrahepatic cholangiocarcinoma. Clin Cancer Res 12: 6611-6616,2006.
50. Benckert C, Jonas S, Cramer T, Schäfer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, Höcker M and Rosewicz S: Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63: 1083-1092, 2003.
51. Terada T, Okada Y and Nakanuma Y: Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23: 1341-1344, 1996.
52. Maeda T, Lahousse S, Tamaki S, Tamaki S, Enjoji M, Wands JR and de la Monte SM: Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 38: 615-622, 2003.
53. Perbal B: NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 54: 57-79,2001.
54. Tanaka S, Sugimachi K, Kameyama T, Maehara S, Shirabe K, Shimada M, Wands JR and Maehara Y: Human WISPlv, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37: 1122-1129, 2003.
55. Ashida K, Terada T, Kitamura Y and Kaibara N: Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 27: 974-982,1998.
56. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD and Gendler SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22: 1324- 1332,2003.
57. Kanno N, LeSage G, Phinizy JL, Glaser S, Francis H and Alpini G: Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B- Raf activities. Hepatology 35: 1329-1340, 2002.
58. Elsing C, Hubner C, Fitscher BA, Kassner A and Stremmel W: Muscarinic acetylcholine receptor stimulation of biliary epithelial cells and its effect on bile secretion in the isolated perfused liver. Hepatology 25: 804-813,1997.
59. Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T, Taffetani S, Marzioni M, Summers R, Reichenbach R and. Alpini G: Gamma-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 65: 11437-11446,2005.
60. 2+- dependent protein kinase C-alpha. J Hepatol 34: 284-291, 2001.
61. Bold RJ, Alpard V, Ishizuka J and Townsend Jr CM: Growth- regulatory effect of gastrin on human colon cancer cell lines is determined by protein kinase a isoform content. Regul Pept 53: 61-70, 1994.
62. Hudd C, Euhus DM, LaRegina MC Herbold DR, Palmer DC and Johnson FE: Effect of cholecystokinin on human cholangiocarcinoma xenografted into nude mice. Cancer Res 45: 1372- 1377,1985.
63. Zhao B, Zhao H, Zhao N and Zhu XG: Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment. J Hepatobiliary Pancreat Surg 9: 497-502, 2002.
64. Tan CK, Podila PV, Taylor JE, Nagorney DM, Wiseman GA, Gores GJ and LaRusso NF: Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 108: 1908-1916, 1995.
65. Sampson LK, Vickers SM, Ying W and Phillips JO: Tamoxifen- mediated growth inhibition of human cholangiocarcinoma. Cancer Res 57: 1743-1749, 1997.
66. Ahn EY, Pan G, Oh JH, Tytler EM and McDonald JM: The combination of calmodulin antagonists and interferongamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells. Am J Pathol 163: 2053- 2063,2003.
67. Vickers SM, Jhala NC, Ahn EY, McDonald JM, Pan G and Bland KI: Tamoxifen (TMX)/Fas-induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN- gamma). Ann Surg 235: 872-878, 2002.